Lynn Anne Bristol

Array ( [id] => 17982638 [patent_doc_number] => 20220348674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => NOVEL ANTI-CD40 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/245345 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537534 [patent_doc_number] => 20230242632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/922230 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19900 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17922230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228683 [patent_doc_number] => 20210355239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => Antigen-Binding Polypeptide Constructs Comprising Kappa and Lambda Light Chains and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/241181 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299505 [patent_doc_number] => 20210395344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => VARIANT NUCLEIC ACID LIBRARIES FOR CORONAVIRUS [patent_app_type] => utility [patent_app_number] => 17/242179 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17242179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339321 [patent_doc_number] => 12049499 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Anti-CD19 antibodies and uses therof [patent_app_type] => utility [patent_app_number] => 17/239010 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 23566 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 512 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449525 [patent_doc_number] => 20230190801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => NATURAL KILLER (NK) CELL COMPOSITIONS AND METHODS FOR GENERATING SAME [patent_app_type] => utility [patent_app_number] => 17/920776 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -122 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449525 [patent_doc_number] => 20230190801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => NATURAL KILLER (NK) CELL COMPOSITIONS AND METHODS FOR GENERATING SAME [patent_app_type] => utility [patent_app_number] => 17/920776 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -122 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20200421 [patent_doc_number] => 12403186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Allogeneic tumor cell vaccine [patent_app_type] => utility [patent_app_number] => 17/233124 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 48 [patent_no_of_words] => 47621 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 349 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20200421 [patent_doc_number] => 12403186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Allogeneic tumor cell vaccine [patent_app_type] => utility [patent_app_number] => 17/233124 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 48 [patent_no_of_words] => 47621 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 349 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022343 [patent_doc_number] => 20210246214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => ANTITUMOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/301869 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20200421 [patent_doc_number] => 12403186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Allogeneic tumor cell vaccine [patent_app_type] => utility [patent_app_number] => 17/233124 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 48 [patent_no_of_words] => 47621 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 349 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007130 [patent_doc_number] => 20210238291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/230240 [patent_app_country] => US [patent_app_date] => 2021-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17230240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067330 [patent_doc_number] => 20210269545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => COMPOSITE BINDING MOLECULES TARGETING IMMUNOSUPPRESSIVE B CELLS [patent_app_type] => utility [patent_app_number] => 17/229751 [patent_app_country] => US [patent_app_date] => 2021-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17229751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414116 [patent_doc_number] => 20220049020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => TETRAVALENT MULTISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/224058 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38429 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 206 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17141743 [patent_doc_number] => 20210309755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => Anti-Mesothelin Antigen-Binding Molecules and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/223871 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21826 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17223871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436047 [patent_doc_number] => 20230183341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => METHODS OF USE OF ANTI-TREM2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/916728 [patent_app_country] => US [patent_app_date] => 2021-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79622 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -78 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391444 [patent_doc_number] => 20230159662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => ANTIBODY COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/916275 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 324 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18323383 [patent_doc_number] => 20230121511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => METHOD FOR PRODUCING MULTISPECIFIC ANTIGEN-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/914432 [patent_app_country] => US [patent_app_date] => 2021-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20193615 [patent_doc_number] => 20250270325 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => STABILIZED IGG4 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/907683 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962961 [patent_doc_number] => 20210214460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => BCMA Monoclonal Antibody-Drug Conjugate [patent_app_type] => utility [patent_app_number] => 17/215479 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17215479 [rel_patent_id] =>[rel_patent_doc_number] =>)